Healthcare / Diagnostics & ResearchNasdaqCM
$5.60
+0.10 (+1.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-8.2M · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-310.9%
↓Gross Margin
N/A
•Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-7.0M · FCF $-8.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | — | — | — | — | — | — | $0.00 | $0.00 | $6174.00 | $351622.00 | $515582.00 |
| Net Income | $-7.0M | $-7.0M | $-11.5M | $-10.1M | $-13.2M | $-11.2M | $-11.7M | $-13.3M | $-9.8M | $-5.4M | $-2.8M |
| EBITDA | $-5.6M | $-5.6M | $-10.6M | $-10.2M | $-12.9M | $-11.4M | $-11.4M | $-10.8M | $-9.0M | $-4.6M | $-1.7M |
| EPS | -8.93 | -8.93 | -56.94 | -2766.85 | -7980.00 | -9712.50 | -22050.00 | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — | 100.0% | 50.9% | 54.3% |
| Operating Margin | — | — | — | — | — | — | — | — | -146080.5% | -1315.6% | -347.5% |
| Net Margin | — | — | — | — | — | — | — | — | -158669.6% | -1529.2% | -538.3% |
| Balance Sheet | |||||||||||
| Debt/Equity | 0.22 | 0.22 | 0.23 | 0.07 | 0.08 | 0.05 | — | — | — | — | — |
| Current Ratio | 0.64 | 0.64 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $-8.2M | $-8.2M | $-7.4M | $-9.6M | $-13.0M | $-11.2M | $-10.8M | $-8.6M | $-7.8M | $-3.3M | — |
| Returns | |||||||||||
| ROE | -310.9% | -310.9% | -449.5% | -177.8% | -182.9% | -104.1% | -163.6% | -279.5% | -156.8% | -101.9% | 310.5% |
| Valuation | |||||||||||
| P/B | 1.95 | 1.95 | 0.53 | 1.64 | 1.99 | — | — | — | — | — | — |
| Growth & Yield | |||||||||||
| Revenue Growth | — | — | — | — | — | — | — | -100.0% | -98.2% | -31.8% | — |
| EPS Growth | 84.3% | 84.3% | 97.9% | 65.3% | — | 56.0% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+67.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-56.94 → -8.93
Residual
+67.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.